<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rpmj</journal-id><journal-title-group><journal-title xml:lang="ru">Research'n Practical Medicine Journal</journal-title><trans-title-group xml:lang="en"><trans-title>Research and Practical Medicine Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2410-1893</issn><publisher><publisher-name>"QUASAR", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17709/2409-2231-2020-7-1-1</article-id><article-id custom-type="elpub" pub-id-type="custom">rpmj-495</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные статьи. Онкология, лучевая терапия</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original Articles. Оncology</subject></subj-group></article-categories><title-group><article-title>Прогностическое значение маркеров Ki-67 и P16/INK4a в гистологической диагностике степени дисплазии шейки матки</article-title><trans-title-group xml:lang="en"><trans-title>Prognostic relevance of Ki-67 and P16/INK4a markers in histological diagnosis of cervical dysplasia</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5399-6636</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Димитриади</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Dimitriadi</surname><given-names>T. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Димитриади Татьяна Александровна – к.м.н., руководитель Областного центра патологии шейки матки </p><p>Доцент кафедры персонализированной и трансляционной медицины</p><p>Адрес: 344011, г. Ростов-на-Дону, ул. Пушкинская, д. 127</p><p>SPIN: 3656-8744</p></bio><bio xml:lang="en"><p>Tatyana A. Dimitriadi – Cand. Sci. (Med.), head of the Regional Center of Cervical Pathology</p><p>Associate Professor of the Department of personalized and translational medicine </p><p>SPIN: 3656-8744</p></bio><email xlink:type="simple">tdimitriadi@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бурцев</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Burtsev</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бурцев Дмитрий Владимирович – д.м.н., главный врач</p><p>доцент кафедры онкологии</p><p>Заведующий кафедрой персонализированной и трансляционной медицины </p></bio><bio xml:lang="en"><p>Dmitrii V. Burtsev – Dr. Sci. (Med.), chief physician</p><p>associate professor </p><p>Head of the Department of personalized and translational medicine</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дженкова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Dzhenkova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дженкова Елена Алексеевна – д.б.н., доцент, ученый секретарь </p><p>SPIN: 6206–6222</p></bio><bio xml:lang="en"><p>Elena A. Dzhenkova – Dr. Sci. (Biol.), associate professor, scientific secretary </p><p>SPIN: 6206–6222</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9820-8373</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гудцкова</surname><given-names>Т. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Gudtskova</surname><given-names>T. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гудцкова Татьяна Николаевна – к.б.н., врач-лаборант патолого-анатомического отделения </p><p>SPIN: 7010–5883</p></bio><bio xml:lang="en"><p>Tatyana N. Gudtskova – Cand. Sci. (Biol.), laboratory doctor of the pathology department</p><p>SPIN: 7010–5883</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Двадненко</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Dvadnenko</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Двадненко Константин Владимирович – к.м.н., врач-патологоанатом лаборатории клинической патоморфологии и молекулярно-биологических исследований </p><p>SPIN: 4497–1769</p></bio><bio xml:lang="en"><p>Konstantin V. Dvadnenko – Cand. Sci. (Med.), pathologist of the laboratory of clinical pathomorphology and molecular biological research</p><p>SPIN: 4497–1769</p></bio><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГАУ РО «Областной консультативно-диагностический центр»; &#13;
ФГБОУ ВО «Ростовский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Regional Advisory and Diagnostic Centre; &#13;
Rostov State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГАУ РО «Областной консультативно-диагностический центр»; ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации&#13;
ФГБОУ ВО «Ростовский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Regional Advisory and Diagnostic Centre; &#13;
National Medical Research Centre for Oncology;&#13;
Rostov State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Centre for Oncology of the Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ГАУ РО «Областной консультативно-диагностический центр»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Regional Advisory and Diagnostic Centre</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>12</day><month>03</month><year>2020</year></pub-date><volume>7</volume><issue>1</issue><fpage>8</fpage><lpage>15</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Димитриади Т.А., Бурцев Д.В., Дженкова Е.А., Гудцкова Т.Н., Двадненко К.В., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Димитриади Т.А., Бурцев Д.В., Дженкова Е.А., Гудцкова Т.Н., Двадненко К.В.</copyright-holder><copyright-holder xml:lang="en">Dimitriadi T.A., Burtsev D.V., Dzhenkova E.A., Gudtskova T.N., Dvadnenko K.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpmj.ru/rpmj/article/view/495">https://www.rpmj.ru/rpmj/article/view/495</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Определить количественные параметры молекулярных маркеров Ki‑67 и p16/INK4a при CIN 1–3 и установить возможность применения их для повышения качества диагностики по гистологическим образцам.</p></sec><sec><title>Пациенты и методы</title><p>Пациенты и методы. Изучен биопсийный материал шейки матки 71 пациентки, являющейся носительницами ВПЧ-инфекции. Иммуногистохимическим методом (ИГХ) в биоптатах определена экспрессия маркеров Ki‑67 и p16/INK4a.</p></sec><sec><title>Результаты</title><p>Результаты. По результатам стандартного гистологического исследования распределение пациенток по группам произошло следующим образом: CIN1–18, CIN2–39, CIN3–14 человек. Установлено, что выраженность экспрессии исследованных маркеров ассоциирована со степенью тяжести диспластических изменений в ткани шейки матки. По изученным маркерам определены наиболее характерные молекулярные профили для степеней дисплазии: CIN1 – Ki‑67–15–25%, p16/INK4a – 10–15%; CIN2 – Ki‑67–70–80%, p16/INK4a – 65–70%; CIN3 – Ki‑67–85–90%, p16/INK4a – 90–95%. Выявлена гетерогенностьпо экспрессии этих маркеров в группе CIN2: в 7 случаях (22,6%) молекулярный профиль соответствовал CIN1, в 1 случае (3,6%) –CIN3. Приведены клинические примеры использования ИГХ-профиля для уточнения степени CIN.</p></sec><sec><title>Заключение</title><p>Заключение. Использование ИГХ-исследования с Ki‑67 и p16/INK4a в дополнение к стандартному гистологическому исследованию позволяет объективизировать первичный диагноз степени CIN, а также выделить больных с высоким и низким риском развития тяжелых повреждений. Особенно это актуально для группы CIN2, наиболее проблематичной в плане как гистологической оценки, так и тактики клинического ведения пациенток. Использование ИГХ при первичной диагностике будет способствовать: улучшению информативности множественной прицельной и петлевой эксцизионной биопсий; снижению числа рецидивов ввиду неадекватного лечения; устранению необоснованного применения такого травматичного метода, как конизация (особенно у женщин детородного возраста).</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose of the study</title><p>Purpose of the study. To determine the quantitative parameters of the molecular markers Ki‑67 and p16/INK4a at CIN 1–3 and to establish the possibility of using them to improve the quality of diagnosis by histological samples.</p></sec><sec><title>Patients and methods</title><p>Patients and methods. Biopsy material of the cervix was studied in 71 patients who were carriers of HPV infection. Immunohistochemical method (IHC) in biopsy specimens determined the expression of Ki‑67 and p16/INK4a markers.</p></sec><sec><title>Results</title><p>Results. According to the results of a standard histological examination, the distribution of patientsinto groups occurred as follows: CIN 1–18, in CIN 2–39, in CIN 3–14 patients. It was found that the expression of the studied markers is associated with the severity of dysplastic changes in the tissue of the cervix. By the studied marker, the most characteristic molecular profiles for the degrees of dysplasia were determined: CIN1 – Ki‑67–15–25%, p16/INK4a 10–15%; CIN2 – Ki‑67–70–80%, p16/INK4a – 65–70%; CIN3 – Ki‑67–85–90%, p16/INK4a – 90–95%. Heterogeneity was revealed in the expression of these markersin the CIN 2 group: in 7 cases (22,6%), the molecular profile corresponded to CIN 1, in 1 case (3,6%) to CIN 3. Clinical examples of using the IHC profile to clarify the degree of CIN are given.</p></sec><sec><title>Conclusion</title><p>Conclusion. The use of an IHC study with Ki‑67 and p16/INK4a, in addition to the standard histological examination, makes it possible to objectify the initial diagnosis of the degree of CIN, as well as to identify patients with a high and low risk of developing severe injuries. This is especially true for the CIN2 group, the most problematic in terms of histological evaluation and tactics of clinical management of patients. The use of IHC in the initial diagnosis will contribute to: improving the information content of multiple aimed and loop excisional biopsies; reduction in relapse due to inadequate treatment; eliminating the unreasonable use of such a traumatic method as conization (especially in women of childbearing age).</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>шейка матки</kwd><kwd>цервикальная интраэпителиальная неоплазия (CIN)</kwd><kwd>иммуногистохимия (ИГХ)</kwd><kwd>Ki-67</kwd><kwd>p16/INK4a</kwd><kwd>вирус папилломы человека (ВПЧ)</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cervix</kwd><kwd>cervical intraepithelial neoplasia (CIN)</kwd><kwd>immunohistochemistry (IHC)</kwd><kwd>Ki-67</kwd><kwd>p16/INK4a</kwd><kwd>human papillomavirus (HPV)</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Состояние онкологической помощи населению России в 2018 году. Под редакцией А.Д. Каприна, В.В. Старинского, Г.В. Петровой.М.: 2019, 236 с.</mixed-citation><mixed-citation xml:lang="en">The status of cancer care for the population of Russia in 2018. Edited by Kaprin AD, Starinskii VV, Petrova GV. Мoscow: 2019, 236 p. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Wyber R, Vaillancourt S, Perry W, Mannava P, Folaranmi T, Celi LA. Big data in global health: improving health in low- and middle-income countries. Bull World Health Organ. 2015 Mar 1; 93 (3):203–208. https://doi.org/10.2471/BLT.14.139022</mixed-citation><mixed-citation xml:lang="en">Wyber R, Vaillancourt S, Perry W, Mannava P, Folaranmi T, Celi LA. Big data in global health: improving health in low- and middle-income countries. Bull World Health Organ. 2015 Mar 1; 93 (3):203–208. https://doi.org/10.2471/BLT.14.139022</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lowy DR. HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. J ClinInvest. 2016 Jan; 126 (1):5–11. https://doi. org/10.1172/JCI85446</mixed-citation><mixed-citation xml:lang="en">Lowy DR. HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. J ClinInvest. 2016 Jan; 126 (1):5–11. https://doi. org/10.1172/JCI85446</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Брико Н.И., Лопухов П.Д. Необходимость контроля ВПЧ-ассоциированных заболеваний. Эпидемиология и вакцинопрофилактика. 2017; 16 (2 (93)):10–15.</mixed-citation><mixed-citation xml:lang="en">Briko NI, Lopukhov PD. Need to control HPV-associated diseases. Epidemiology and Vaccinal Prevention 2017; 16 (2 (93)):10–15. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Committee on Practice Bulletins Gynecology. Practice Bulletin No. 168: Cervical Cancer Screening and Prevention. ObstetGynecol. 2016; 128 (4): e111 e130. https://doi. org/10.1097/AOG.0000000000001708</mixed-citation><mixed-citation xml:lang="en">Mezhevitinova EA, Abakarova PR, KhlebkovaYuS. Precancerous cervical lesions. Medical Council.2016; (12):112–118. (In Russian). https://doi.org/10.21518/2079–701X 2016–12–112–118</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Серова О.Ф., Зароченцева Н.В., Важнова В.М., Кешьян Л.В. Беременность уженщин после лечения цервикальных интраэпителиальных неоплазий. Эффективная фармакотерапия. 2010; (1):28–32.</mixed-citation><mixed-citation xml:lang="en">Committee on Practice Bulletins Gynecology. Practice Bulletin No. 168: Cervical Cancer Screening and Prevention. Obstet Gynecol. 2016; 128 (4): e111–130. https://doi. org/10.1097/AOG.0000000000001708</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Бадретдинова Ф.Ф., Глебова Н.Н., Короткова Л.А., Хасанов А. Г., Трубин В.Б. Акушерская травма и рубцовая деформация шейки матки. Некоторые спорные вопросы проблемы (обзор литературы). Научное обозрение медицинские науки. 2016; (5):23–31.</mixed-citation><mixed-citation xml:lang="en">Serova OF, Zarochentseva NV, Vazhnova VM, Kesh'yan LV. Pregnancy in women after treatment of cervical intraepithelial neoplasia. Effective Pharmacotherapy. 2010; (1):28–32. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Руководство по амбулаторно-поликлинической помощи в акушерстве и гинекологии. Под редакцией В.Н. Серова, Г. Т. Сухих, В.Н. Прилепской, В. Е. Радзинского. 2 е издание.М.: ГЭОТАР-Медиа, 2016.</mixed-citation><mixed-citation xml:lang="en">Badretdinova FF, Glebova NN, Korotkova LA, Khasanov AG, Trubin VB. Obstetric trauma and cicatricial deformity of the cervix. some controversial issues of the problem (literature review). Scientific Review Medical Sciences. 2016; (5):23–31. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ежемесячный мониторинг социально-экономического положения и самочувствия населения: 2015 г. – ноябрь 2018 г. Российская академия народного хозяйства и государственной службы при Президенте Российской Федерации; под ред. Т.М. Малевой, 2018.</mixed-citation><mixed-citation xml:lang="en">Guidelines for outpatient care in obstetrics and gynecology. Edited by V.N. Serova, G. T. Sukhikh, V.N. Prilepsky, V. E. Radzinsky. 2nd edition.M.: GEOTAR-Media, 2016. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Hebbar A, Murthy VS. Role of p16/INK4a and Ki 67 as specific biomarkers for cervical intraepithelial neoplasia: An institutional study. J LabPhysicians. 2017 Jun; 9 (2):104–110. https://doi. org/10.4103/0974–2727.199630</mixed-citation><mixed-citation xml:lang="en">Monthly monitoring of the socio-economic situation and well-being of the population: 2015 – November 2018, Russian Presidential Academy of National Economy and Public Administration; under the editorship of T.M. Maleva. 2018. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Bergeron C, Ikenberg H, Sideri M, Denton K, Bogers J, Schmidt D, et al. Prospective evaluation of p16/Ki 67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. CancerCytopathol. 2015 Jun; 123 (6):373– 381. https://doi.org/10.1002/cncy.21542</mixed-citation><mixed-citation xml:lang="en">Hebbar A, Murthy VS. Role of p16/INK4a and Ki 67 as specific biomarkers for cervical intraepithelial neoplasia: An institution al study. J Lab Physicians. 2017 Jun; 9 (2):104–110. https://doi. org/10.4103/0974–2727.199630</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Branca M, Ciotti M, Giorgi C, Santini D, Di Bonito L, Costa S, et al. Predicting high-risk human papillomavirus infection, progression of cervical intraepithelial neoplasia, and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modeling. Int J Gynecol Pathol. 2008 Apr; 27 (2):265–273. https://doi. org/10.1097/PGP.0b013e318159cbc0</mixed-citation><mixed-citation xml:lang="en">Bergeron C, Ikenberg H, Sideri M, Denton K, Bogers J, Schmidt D, et al. Prospective evaluation of p16/Ki 67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. Cancer Cytopathol. 2015 Jun; 123 (6):373– 381. https://doi.org/10.1002/cncy.21542</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Трухачёва Н.В. Медицинская статистика: учебное Пособие. Ростов на-Дону: Феникс, 2017.</mixed-citation><mixed-citation xml:lang="en">Branca M, Ciotti M, Giorg C, Santini D, Di Bonito L, Costa S, et al. Predicting high-risk human papillomavirus infection, progression of cervical intraepithelial neoplasia, and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modeling. Int.J. Gynecol. Pathol. 2008; 27 (2):265–273. https://doi. org/10.1097/PGP.0b013e318159cbc0.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Межевитинова Е.А., Абакарова П. Р., Хлебкова Ю.С. Предраковые поражения шейки матки тактика ведения. Медицинский совет. 2016; (12):112–118. https://doi.org/ 10.21518/2079–701X 2016–12–112–118</mixed-citation><mixed-citation xml:lang="en">Trukhacheva NV. Medical Statistics: A Training Manual. Rostov-on-Don: Phoenix, 2017. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">US Preventive Services Task Force Recommendation Statement. Screening for Cervical Cancer. JAMA. 2018;320 (7):674–686. https://doi.org/10.1001/jama.2018.10897</mixed-citation><mixed-citation xml:lang="en">US Preventive Services Task Force Recommendation Statement. Screening for Cervical Cancer. JAMA. 2018;320 (7):674–686. https://doi.org/10.1001/jama.2018.10897</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
